Company profile for Solid Biosciences

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Solid Biosciences is a life science company focused on developing transformative treatments to improve the lives of patients living with Duchenne muscular dystrophy (Duchenne). Disease-focused and founded by a family directly impacted, our mandate is simple yet comprehensive – work to address the disease at its core by correcting the underlying mutation with our gene therapy candidate, SGT-001. Solid has been purpose-built t...
Solid Biosciences is a life science company focused on developing transformative treatments to improve the lives of patients living with Duchenne muscular dystrophy (Duchenne). Disease-focused and founded by a family directly impacted, our mandate is simple yet comprehensive – work to address the disease at its core by correcting the underlying mutation with our gene therapy candidate, SGT-001. Solid has been purpose-built to advance the best science and accelerate the discovery and development of treatments that may benefit all patients with this devastating disease. Learn more about how we were founded and what drives us every day.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
141 Portland Street Fifth Floor Cambridge, MA 02139
Telephone
Telephone
(617) 337-4680
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/12/01/3197428/0/en/Solid-Biosciences-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html

GLOBENEWSWIRE
01 Dec 2025

https://www.globenewswire.com/news-release/2025/12/01/3196939/0/en/Solid-Biosciences-Receives-FDA-Rare-Pediatric-Disease-Designation-for-SGT-212-Dual-Route-of-Administration-Gene-Therapy-for-Friedreich-s-Ataxia.html

GLOBENEWSWIRE
01 Dec 2025

https://www.globenewswire.com/news-release/2025/11/17/3189051/0/en/Solid-Biosciences-Announces-Licensing-Agreement-with-Andelyn-Biosciences-for-the-Use-of-Proprietary-Next-Generation-Capsid-AAV-SLB101.html

GLOBENEWSWIRE
17 Nov 2025

https://www.globenewswire.com/news-release/2025/11/11/3185347/0/en/Solid-Biosciences-to-Participate-at-Upcoming-Investor-Conferences.html

GLOBENEWSWIRE
11 Nov 2025

https://www.globenewswire.com/news-release/2025/11/06/3182474/0/en/Solid-Biosciences-Awarded-Innovation-Passport-Designation-Under-the-New-UK-Innovative-Licensing-and-Access-Pathway-for-SGT-003-an-Investigational-Gene-Therapy-for-Duchenne-Muscular.html

GLOBENEWSWIRE
06 Nov 2025

https://www.globenewswire.com/news-release/2025/11/04/3180880/0/en/Solid-Biosciences-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html

GLOBENEWSWIRE
04 Nov 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty